nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—AKR1C1—uterine cancer	0.306	0.633	CbGaD
Mefenamic acid—AKR1C3—Medroxyprogesterone Acetate—uterine cancer	0.24	0.651	CbGbCtD
Mefenamic acid—AKR1C3—uterine cancer	0.178	0.367	CbGaD
Mefenamic acid—AKR1C3—Doxorubicin—uterine cancer	0.0485	0.132	CbGbCtD
Mefenamic acid—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.019	0.0514	CbGbCtD
Mefenamic acid—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0132	0.0359	CbGbCtD
Mefenamic acid—CYP2C8—Progesterone—uterine cancer	0.0126	0.0341	CbGbCtD
Mefenamic acid—PTGS2—Etoposide—uterine cancer	0.0115	0.0313	CbGbCtD
Mefenamic acid—PTGS1—Etoposide—uterine cancer	0.00974	0.0264	CbGbCtD
Mefenamic acid—CYP2C9—Progesterone—uterine cancer	0.00876	0.0238	CbGbCtD
Mefenamic acid—CYP2C8—Etoposide—uterine cancer	0.00562	0.0152	CbGbCtD
Mefenamic acid—AKR1C3—Podofilox—Etoposide—uterine cancer	0.00154	1	CbGdCrCtD
Mefenamic acid—PTGS1—oviduct—uterine cancer	0.00114	0.0663	CbGeAlD
Mefenamic acid—AKR1C2—lymph node—uterine cancer	0.00113	0.0656	CbGeAlD
Mefenamic acid—AKR1C3—myometrium—uterine cancer	0.00103	0.06	CbGeAlD
Mefenamic acid—AKR1C3—uterine cervix—uterine cancer	0.000805	0.0467	CbGeAlD
Mefenamic acid—Acetylsalicylic acid—AKR1C1—uterine cancer	0.000791	0.278	CrCbGaD
Mefenamic acid—AKR1C3—smooth muscle tissue—uterine cancer	0.000782	0.0454	CbGeAlD
Mefenamic acid—AKR1C3—decidua—uterine cancer	0.000767	0.0445	CbGeAlD
Mefenamic acid—PTGS1—artery—uterine cancer	0.000757	0.0439	CbGeAlD
Mefenamic acid—AKR1C3—endometrium—uterine cancer	0.000728	0.0422	CbGeAlD
Mefenamic acid—PTGS2—artery—uterine cancer	0.000724	0.042	CbGeAlD
Mefenamic acid—AKR1C3—mammalian vulva—uterine cancer	0.000704	0.0408	CbGeAlD
Mefenamic acid—AKR1C3—uterus—uterine cancer	0.000671	0.0389	CbGeAlD
Mefenamic acid—Salicylic acid—AKR1C1—uterine cancer	0.000651	0.229	CrCbGaD
Mefenamic acid—Meclofenamic acid—AKR1C3—uterine cancer	0.000606	0.213	CrCbGaD
Mefenamic acid—AKR1C3—female gonad—uterine cancer	0.000549	0.0318	CbGeAlD
Mefenamic acid—AKR1C3—vagina—uterine cancer	0.000545	0.0316	CbGeAlD
Mefenamic acid—Acetylsalicylic acid—TP53—uterine cancer	0.000412	0.145	CrCbGaD
Mefenamic acid—AKR1C3—lymph node—uterine cancer	0.000353	0.0205	CbGeAlD
Mefenamic acid—PTGS2—myometrium—uterine cancer	0.00035	0.0203	CbGeAlD
Mefenamic acid—CYP2C8—renal system—uterine cancer	0.000328	0.0191	CbGeAlD
Mefenamic acid—CYP2C8—endometrium—uterine cancer	0.000318	0.0184	CbGeAlD
Mefenamic acid—PTGS1—epithelium—uterine cancer	0.000287	0.0167	CbGeAlD
Mefenamic acid—PTGS1—uterine cervix—uterine cancer	0.000285	0.0165	CbGeAlD
Mefenamic acid—PTGS1—smooth muscle tissue—uterine cancer	0.000277	0.0161	CbGeAlD
Mefenamic acid—PTGS2—epithelium—uterine cancer	0.000275	0.0159	CbGeAlD
Mefenamic acid—PTGS2—uterine cervix—uterine cancer	0.000272	0.0158	CbGeAlD
Mefenamic acid—PTGS1—renal system—uterine cancer	0.000266	0.0155	CbGeAlD
Mefenamic acid—PTGS2—smooth muscle tissue—uterine cancer	0.000265	0.0153	CbGeAlD
Mefenamic acid—CYP2C8—female reproductive system—uterine cancer	0.000263	0.0153	CbGeAlD
Mefenamic acid—PTGS1—endometrium—uterine cancer	0.000258	0.0149	CbGeAlD
Mefenamic acid—PTGS2—renal system—uterine cancer	0.000255	0.0148	CbGeAlD
Mefenamic acid—PTGS1—mammalian vulva—uterine cancer	0.000249	0.0145	CbGeAlD
Mefenamic acid—PTGS2—endometrium—uterine cancer	0.000246	0.0143	CbGeAlD
Mefenamic acid—CYP2C8—vagina—uterine cancer	0.000238	0.0138	CbGeAlD
Mefenamic acid—PTGS1—uterus—uterine cancer	0.000237	0.0138	CbGeAlD
Mefenamic acid—CYP2C9—female reproductive system—uterine cancer	0.000234	0.0136	CbGeAlD
Mefenamic acid—PTGS2—uterus—uterine cancer	0.000227	0.0132	CbGeAlD
Mefenamic acid—PTGS1—female reproductive system—uterine cancer	0.000213	0.0124	CbGeAlD
Mefenamic acid—PTGS2—female reproductive system—uterine cancer	0.000204	0.0118	CbGeAlD
Mefenamic acid—Diclofenac—CXCL8—uterine cancer	0.000204	0.0716	CrCbGaD
Mefenamic acid—PTGS1—female gonad—uterine cancer	0.000194	0.0113	CbGeAlD
Mefenamic acid—PTGS1—vagina—uterine cancer	0.000193	0.0112	CbGeAlD
Mefenamic acid—PTGS2—female gonad—uterine cancer	0.000186	0.0108	CbGeAlD
Mefenamic acid—PTGS2—vagina—uterine cancer	0.000184	0.0107	CbGeAlD
Mefenamic acid—Ketoprofen—CXCL8—uterine cancer	0.00018	0.0634	CrCbGaD
Mefenamic acid—PTGS1—lymph node—uterine cancer	0.000125	0.00724	CbGeAlD
Mefenamic acid—PTGS2—lymph node—uterine cancer	0.000119	0.00692	CbGeAlD
Mefenamic acid—Erythema multiforme—Etoposide—uterine cancer	0.000109	0.00175	CcSEcCtD
Mefenamic acid—Coma—Doxorubicin—uterine cancer	0.000109	0.00175	CcSEcCtD
Mefenamic acid—Oesophagitis—Doxorubicin—uterine cancer	0.000109	0.00175	CcSEcCtD
Mefenamic acid—Anorexia—Dactinomycin—uterine cancer	0.000108	0.00173	CcSEcCtD
Mefenamic acid—Ecchymosis—Doxorubicin—uterine cancer	0.000108	0.00173	CcSEcCtD
Mefenamic acid—Bladder pain—Doxorubicin—uterine cancer	0.000108	0.00173	CcSEcCtD
Mefenamic acid—Photosensitivity—Epirubicin—uterine cancer	0.000106	0.00171	CcSEcCtD
Mefenamic acid—Dizziness—Progesterone—uterine cancer	0.000106	0.0017	CcSEcCtD
Mefenamic acid—Vascular purpura—Epirubicin—uterine cancer	0.000104	0.00168	CcSEcCtD
Mefenamic acid—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000104	0.00167	CcSEcCtD
Mefenamic acid—Hepatic failure—Epirubicin—uterine cancer	0.000104	0.00167	CcSEcCtD
Mefenamic acid—Sepsis—Doxorubicin—uterine cancer	0.000103	0.00166	CcSEcCtD
Mefenamic acid—Cardiac failure congestive—Epirubicin—uterine cancer	0.000103	0.00165	CcSEcCtD
Mefenamic acid—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000103	0.00165	CcSEcCtD
Mefenamic acid—Alopecia—Etoposide—uterine cancer	0.000102	0.00163	CcSEcCtD
Mefenamic acid—Vomiting—Progesterone—uterine cancer	0.000102	0.00163	CcSEcCtD
Mefenamic acid—Lymphadenopathy—Doxorubicin—uterine cancer	0.000101	0.00163	CcSEcCtD
Mefenamic acid—Rash—Progesterone—uterine cancer	0.000101	0.00162	CcSEcCtD
Mefenamic acid—Dermatitis—Progesterone—uterine cancer	0.000101	0.00162	CcSEcCtD
Mefenamic acid—Headache—Progesterone—uterine cancer	0.0001	0.00161	CcSEcCtD
Mefenamic acid—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	9.93e-05	0.00159	CcSEcCtD
Mefenamic acid—Dermatitis exfoliative—Epirubicin—uterine cancer	9.9e-05	0.00159	CcSEcCtD
Mefenamic acid—Photosensitivity—Doxorubicin—uterine cancer	9.85e-05	0.00158	CcSEcCtD
Mefenamic acid—Decreased appetite—Dactinomycin—uterine cancer	9.84e-05	0.00158	CcSEcCtD
Mefenamic acid—Renal impairment—Epirubicin—uterine cancer	9.82e-05	0.00157	CcSEcCtD
Mefenamic acid—Purpura—Epirubicin—uterine cancer	9.69e-05	0.00156	CcSEcCtD
Mefenamic acid—Vascular purpura—Doxorubicin—uterine cancer	9.66e-05	0.00155	CcSEcCtD
Mefenamic acid—Anaphylactoid reaction—Epirubicin—uterine cancer	9.65e-05	0.00155	CcSEcCtD
Mefenamic acid—Hepatic failure—Doxorubicin—uterine cancer	9.62e-05	0.00154	CcSEcCtD
Mefenamic acid—Dizziness—Medroxyprogesterone Acetate—uterine cancer	9.6e-05	0.00154	CcSEcCtD
Mefenamic acid—Cardiac failure congestive—Doxorubicin—uterine cancer	9.53e-05	0.00153	CcSEcCtD
Mefenamic acid—Nausea—Progesterone—uterine cancer	9.51e-05	0.00153	CcSEcCtD
Mefenamic acid—Hyponatraemia—Epirubicin—uterine cancer	9.38e-05	0.0015	CcSEcCtD
Mefenamic acid—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	9.34e-05	0.0015	CcSEcCtD
Mefenamic acid—Feeling abnormal—Dactinomycin—uterine cancer	9.33e-05	0.0015	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Etoposide—uterine cancer	9.31e-05	0.00149	CcSEcCtD
Mefenamic acid—Anaemia—Etoposide—uterine cancer	9.28e-05	0.00149	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Dactinomycin—uterine cancer	9.26e-05	0.00148	CcSEcCtD
Mefenamic acid—Vomiting—Medroxyprogesterone Acetate—uterine cancer	9.23e-05	0.00148	CcSEcCtD
Mefenamic acid—Dermatitis exfoliative—Doxorubicin—uterine cancer	9.16e-05	0.00147	CcSEcCtD
Mefenamic acid—Rash—Medroxyprogesterone Acetate—uterine cancer	9.15e-05	0.00147	CcSEcCtD
Mefenamic acid—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	9.14e-05	0.00147	CcSEcCtD
Mefenamic acid—Headache—Medroxyprogesterone Acetate—uterine cancer	9.09e-05	0.00146	CcSEcCtD
Mefenamic acid—Renal impairment—Doxorubicin—uterine cancer	9.08e-05	0.00146	CcSEcCtD
Mefenamic acid—Malaise—Etoposide—uterine cancer	9.05e-05	0.00145	CcSEcCtD
Mefenamic acid—Vertigo—Etoposide—uterine cancer	9.02e-05	0.00145	CcSEcCtD
Mefenamic acid—Leukopenia—Etoposide—uterine cancer	8.99e-05	0.00144	CcSEcCtD
Mefenamic acid—Purpura—Doxorubicin—uterine cancer	8.97e-05	0.00144	CcSEcCtD
Mefenamic acid—Abdominal pain—Dactinomycin—uterine cancer	8.95e-05	0.00144	CcSEcCtD
Mefenamic acid—Body temperature increased—Dactinomycin—uterine cancer	8.95e-05	0.00144	CcSEcCtD
Mefenamic acid—Anaphylactoid reaction—Doxorubicin—uterine cancer	8.93e-05	0.00143	CcSEcCtD
Mefenamic acid—Loss of consciousness—Etoposide—uterine cancer	8.82e-05	0.00142	CcSEcCtD
Mefenamic acid—Convulsion—Etoposide—uterine cancer	8.7e-05	0.0014	CcSEcCtD
Mefenamic acid—Hyponatraemia—Doxorubicin—uterine cancer	8.68e-05	0.00139	CcSEcCtD
Mefenamic acid—Hypertension—Etoposide—uterine cancer	8.67e-05	0.00139	CcSEcCtD
Mefenamic acid—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	8.65e-05	0.00139	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Epirubicin—uterine cancer	8.63e-05	0.00138	CcSEcCtD
Mefenamic acid—Nausea—Medroxyprogesterone Acetate—uterine cancer	8.62e-05	0.00138	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	8.49e-05	0.00136	CcSEcCtD
Mefenamic acid—Discomfort—Etoposide—uterine cancer	8.44e-05	0.00135	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Epirubicin—uterine cancer	8.41e-05	0.00135	CcSEcCtD
Mefenamic acid—Gastritis—Epirubicin—uterine cancer	8.27e-05	0.00133	CcSEcCtD
Mefenamic acid—Confusional state—Etoposide—uterine cancer	8.26e-05	0.00133	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Etoposide—uterine cancer	8.19e-05	0.00131	CcSEcCtD
Mefenamic acid—Infection—Etoposide—uterine cancer	8.14e-05	0.00131	CcSEcCtD
Mefenamic acid—Asthenia—Dactinomycin—uterine cancer	8.12e-05	0.0013	CcSEcCtD
Mefenamic acid—Asthma—Epirubicin—uterine cancer	8.08e-05	0.0013	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Etoposide—uterine cancer	8.02e-05	0.00129	CcSEcCtD
Mefenamic acid—Tachycardia—Etoposide—uterine cancer	8e-05	0.00128	CcSEcCtD
Mefenamic acid—Eosinophilia—Epirubicin—uterine cancer	8e-05	0.00128	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Doxorubicin—uterine cancer	7.98e-05	0.00128	CcSEcCtD
Mefenamic acid—Skin disorder—Etoposide—uterine cancer	7.96e-05	0.00128	CcSEcCtD
Mefenamic acid—Pancreatitis—Epirubicin—uterine cancer	7.92e-05	0.00127	CcSEcCtD
Mefenamic acid—Anorexia—Etoposide—uterine cancer	7.81e-05	0.00125	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	7.79e-05	0.00125	CcSEcCtD
Mefenamic acid—Diarrhoea—Dactinomycin—uterine cancer	7.75e-05	0.00124	CcSEcCtD
Mefenamic acid—Pancytopenia—Epirubicin—uterine cancer	7.67e-05	0.00123	CcSEcCtD
Mefenamic acid—Hypotension—Etoposide—uterine cancer	7.66e-05	0.00123	CcSEcCtD
Mefenamic acid—Gastritis—Doxorubicin—uterine cancer	7.65e-05	0.00123	CcSEcCtD
Mefenamic acid—Dysuria—Epirubicin—uterine cancer	7.55e-05	0.00121	CcSEcCtD
Mefenamic acid—Asthma—Doxorubicin—uterine cancer	7.47e-05	0.0012	CcSEcCtD
Mefenamic acid—Eosinophilia—Doxorubicin—uterine cancer	7.4e-05	0.00119	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Epirubicin—uterine cancer	7.37e-05	0.00118	CcSEcCtD
Mefenamic acid—Paraesthesia—Etoposide—uterine cancer	7.36e-05	0.00118	CcSEcCtD
Mefenamic acid—Pancreatitis—Doxorubicin—uterine cancer	7.33e-05	0.00118	CcSEcCtD
Mefenamic acid—Dyspnoea—Etoposide—uterine cancer	7.3e-05	0.00117	CcSEcCtD
Mefenamic acid—Hyperglycaemia—Epirubicin—uterine cancer	7.29e-05	0.00117	CcSEcCtD
Mefenamic acid—Somnolence—Etoposide—uterine cancer	7.28e-05	0.00117	CcSEcCtD
Mefenamic acid—Pneumonia—Epirubicin—uterine cancer	7.24e-05	0.00116	CcSEcCtD
Mefenamic acid—Drowsiness—Epirubicin—uterine cancer	7.2e-05	0.00116	CcSEcCtD
Mefenamic acid—Vomiting—Dactinomycin—uterine cancer	7.2e-05	0.00115	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Epirubicin—uterine cancer	7.14e-05	0.00115	CcSEcCtD
Mefenamic acid—Rash—Dactinomycin—uterine cancer	7.14e-05	0.00114	CcSEcCtD
Mefenamic acid—Decreased appetite—Etoposide—uterine cancer	7.12e-05	0.00114	CcSEcCtD
Mefenamic acid—Pancytopenia—Doxorubicin—uterine cancer	7.1e-05	0.00114	CcSEcCtD
Mefenamic acid—Renal failure—Epirubicin—uterine cancer	7.08e-05	0.00114	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Etoposide—uterine cancer	7.07e-05	0.00113	CcSEcCtD
Mefenamic acid—Stomatitis—Epirubicin—uterine cancer	7.02e-05	0.00113	CcSEcCtD
Mefenamic acid—Jaundice—Epirubicin—uterine cancer	7.02e-05	0.00113	CcSEcCtD
Mefenamic acid—Constipation—Etoposide—uterine cancer	7.01e-05	0.00112	CcSEcCtD
Mefenamic acid—Conjunctivitis—Epirubicin—uterine cancer	7e-05	0.00112	CcSEcCtD
Mefenamic acid—Dysuria—Doxorubicin—uterine cancer	6.99e-05	0.00112	CcSEcCtD
Mefenamic acid—Haematuria—Epirubicin—uterine cancer	6.87e-05	0.0011	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Doxorubicin—uterine cancer	6.82e-05	0.00109	CcSEcCtD
Mefenamic acid—Feeling abnormal—Etoposide—uterine cancer	6.75e-05	0.00108	CcSEcCtD
Mefenamic acid—Hyperglycaemia—Doxorubicin—uterine cancer	6.74e-05	0.00108	CcSEcCtD
Mefenamic acid—Nausea—Dactinomycin—uterine cancer	6.72e-05	0.00108	CcSEcCtD
Mefenamic acid—Agranulocytosis—Epirubicin—uterine cancer	6.72e-05	0.00108	CcSEcCtD
Mefenamic acid—Pneumonia—Doxorubicin—uterine cancer	6.7e-05	0.00107	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Etoposide—uterine cancer	6.7e-05	0.00107	CcSEcCtD
Mefenamic acid—Drowsiness—Doxorubicin—uterine cancer	6.66e-05	0.00107	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	6.61e-05	0.00106	CcSEcCtD
Mefenamic acid—Renal failure—Doxorubicin—uterine cancer	6.55e-05	0.00105	CcSEcCtD
Mefenamic acid—Urticaria—Etoposide—uterine cancer	6.51e-05	0.00104	CcSEcCtD
Mefenamic acid—Haemoglobin—Epirubicin—uterine cancer	6.5e-05	0.00104	CcSEcCtD
Mefenamic acid—Jaundice—Doxorubicin—uterine cancer	6.49e-05	0.00104	CcSEcCtD
Mefenamic acid—Stomatitis—Doxorubicin—uterine cancer	6.49e-05	0.00104	CcSEcCtD
Mefenamic acid—Body temperature increased—Etoposide—uterine cancer	6.48e-05	0.00104	CcSEcCtD
Mefenamic acid—Abdominal pain—Etoposide—uterine cancer	6.48e-05	0.00104	CcSEcCtD
Mefenamic acid—Conjunctivitis—Doxorubicin—uterine cancer	6.48e-05	0.00104	CcSEcCtD
Mefenamic acid—Haemorrhage—Epirubicin—uterine cancer	6.46e-05	0.00104	CcSEcCtD
Mefenamic acid—Hepatitis—Epirubicin—uterine cancer	6.46e-05	0.00104	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Epirubicin—uterine cancer	6.38e-05	0.00102	CcSEcCtD
Mefenamic acid—Haematuria—Doxorubicin—uterine cancer	6.35e-05	0.00102	CcSEcCtD
Mefenamic acid—Urethral disorder—Epirubicin—uterine cancer	6.34e-05	0.00102	CcSEcCtD
Mefenamic acid—Agranulocytosis—Doxorubicin—uterine cancer	6.22e-05	0.000997	CcSEcCtD
Mefenamic acid—Erythema multiforme—Epirubicin—uterine cancer	6.11e-05	0.00098	CcSEcCtD
Mefenamic acid—Tinnitus—Epirubicin—uterine cancer	6.03e-05	0.000967	CcSEcCtD
Mefenamic acid—Haemoglobin—Doxorubicin—uterine cancer	6.01e-05	0.000964	CcSEcCtD
Mefenamic acid—Haemorrhage—Doxorubicin—uterine cancer	5.98e-05	0.000959	CcSEcCtD
Mefenamic acid—Hepatitis—Doxorubicin—uterine cancer	5.98e-05	0.000959	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Doxorubicin—uterine cancer	5.91e-05	0.000948	CcSEcCtD
Mefenamic acid—Asthenia—Etoposide—uterine cancer	5.88e-05	0.000943	CcSEcCtD
Mefenamic acid—Urethral disorder—Doxorubicin—uterine cancer	5.86e-05	0.000941	CcSEcCtD
Mefenamic acid—Pruritus—Etoposide—uterine cancer	5.8e-05	0.00093	CcSEcCtD
Mefenamic acid—Arrhythmia—Epirubicin—uterine cancer	5.77e-05	0.000926	CcSEcCtD
Mefenamic acid—Alopecia—Epirubicin—uterine cancer	5.71e-05	0.000916	CcSEcCtD
Mefenamic acid—Mental disorder—Epirubicin—uterine cancer	5.66e-05	0.000908	CcSEcCtD
Mefenamic acid—Erythema multiforme—Doxorubicin—uterine cancer	5.66e-05	0.000907	CcSEcCtD
Mefenamic acid—Diarrhoea—Etoposide—uterine cancer	5.61e-05	0.000899	CcSEcCtD
Mefenamic acid—Tinnitus—Doxorubicin—uterine cancer	5.58e-05	0.000895	CcSEcCtD
Mefenamic acid—Flatulence—Epirubicin—uterine cancer	5.55e-05	0.000889	CcSEcCtD
Mefenamic acid—Tension—Epirubicin—uterine cancer	5.52e-05	0.000886	CcSEcCtD
Mefenamic acid—Nervousness—Epirubicin—uterine cancer	5.47e-05	0.000877	CcSEcCtD
Mefenamic acid—Dizziness—Etoposide—uterine cancer	5.42e-05	0.000869	CcSEcCtD
Mefenamic acid—Arrhythmia—Doxorubicin—uterine cancer	5.34e-05	0.000857	CcSEcCtD
Mefenamic acid—Vision blurred—Epirubicin—uterine cancer	5.3e-05	0.000851	CcSEcCtD
Mefenamic acid—Alopecia—Doxorubicin—uterine cancer	5.29e-05	0.000848	CcSEcCtD
Mefenamic acid—Mental disorder—Doxorubicin—uterine cancer	5.24e-05	0.000841	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Epirubicin—uterine cancer	5.22e-05	0.000838	CcSEcCtD
Mefenamic acid—Vomiting—Etoposide—uterine cancer	5.21e-05	0.000836	CcSEcCtD
Mefenamic acid—Anaemia—Epirubicin—uterine cancer	5.2e-05	0.000834	CcSEcCtD
Mefenamic acid—Rash—Etoposide—uterine cancer	5.17e-05	0.000829	CcSEcCtD
Mefenamic acid—Dermatitis—Etoposide—uterine cancer	5.16e-05	0.000828	CcSEcCtD
Mefenamic acid—Headache—Etoposide—uterine cancer	5.13e-05	0.000823	CcSEcCtD
Mefenamic acid—Flatulence—Doxorubicin—uterine cancer	5.13e-05	0.000823	CcSEcCtD
Mefenamic acid—Tension—Doxorubicin—uterine cancer	5.11e-05	0.00082	CcSEcCtD
Mefenamic acid—Malaise—Epirubicin—uterine cancer	5.07e-05	0.000814	CcSEcCtD
Mefenamic acid—Nervousness—Doxorubicin—uterine cancer	5.06e-05	0.000811	CcSEcCtD
Mefenamic acid—Vertigo—Epirubicin—uterine cancer	5.06e-05	0.000811	CcSEcCtD
Mefenamic acid—Syncope—Epirubicin—uterine cancer	5.05e-05	0.000809	CcSEcCtD
Mefenamic acid—Leukopenia—Epirubicin—uterine cancer	5.04e-05	0.000808	CcSEcCtD
Mefenamic acid—Palpitations—Epirubicin—uterine cancer	4.97e-05	0.000798	CcSEcCtD
Mefenamic acid—Loss of consciousness—Epirubicin—uterine cancer	4.95e-05	0.000793	CcSEcCtD
Mefenamic acid—Vision blurred—Doxorubicin—uterine cancer	4.91e-05	0.000787	CcSEcCtD
Mefenamic acid—Convulsion—Epirubicin—uterine cancer	4.88e-05	0.000782	CcSEcCtD
Mefenamic acid—Nausea—Etoposide—uterine cancer	4.87e-05	0.000781	CcSEcCtD
Mefenamic acid—Hypertension—Epirubicin—uterine cancer	4.86e-05	0.000779	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Doxorubicin—uterine cancer	4.83e-05	0.000775	CcSEcCtD
Mefenamic acid—Anaemia—Doxorubicin—uterine cancer	4.81e-05	0.000772	CcSEcCtD
Mefenamic acid—Anxiety—Epirubicin—uterine cancer	4.77e-05	0.000766	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	4.76e-05	0.000763	CcSEcCtD
Mefenamic acid—Discomfort—Epirubicin—uterine cancer	4.73e-05	0.000759	CcSEcCtD
Mefenamic acid—Malaise—Doxorubicin—uterine cancer	4.7e-05	0.000753	CcSEcCtD
Mefenamic acid—Dry mouth—Epirubicin—uterine cancer	4.69e-05	0.000752	CcSEcCtD
Mefenamic acid—Vertigo—Doxorubicin—uterine cancer	4.68e-05	0.00075	CcSEcCtD
Mefenamic acid—Syncope—Doxorubicin—uterine cancer	4.67e-05	0.000749	CcSEcCtD
Mefenamic acid—Leukopenia—Doxorubicin—uterine cancer	4.66e-05	0.000748	CcSEcCtD
Mefenamic acid—Confusional state—Epirubicin—uterine cancer	4.63e-05	0.000743	CcSEcCtD
Mefenamic acid—Palpitations—Doxorubicin—uterine cancer	4.6e-05	0.000738	CcSEcCtD
Mefenamic acid—Oedema—Epirubicin—uterine cancer	4.59e-05	0.000737	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Epirubicin—uterine cancer	4.59e-05	0.000737	CcSEcCtD
Mefenamic acid—Loss of consciousness—Doxorubicin—uterine cancer	4.58e-05	0.000734	CcSEcCtD
Mefenamic acid—Infection—Epirubicin—uterine cancer	4.56e-05	0.000732	CcSEcCtD
Mefenamic acid—Shock—Epirubicin—uterine cancer	4.52e-05	0.000725	CcSEcCtD
Mefenamic acid—Convulsion—Doxorubicin—uterine cancer	4.51e-05	0.000724	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Epirubicin—uterine cancer	4.5e-05	0.000721	CcSEcCtD
Mefenamic acid—Hypertension—Doxorubicin—uterine cancer	4.5e-05	0.000721	CcSEcCtD
Mefenamic acid—Tachycardia—Epirubicin—uterine cancer	4.48e-05	0.000719	CcSEcCtD
Mefenamic acid—Skin disorder—Epirubicin—uterine cancer	4.46e-05	0.000716	CcSEcCtD
Mefenamic acid—Anxiety—Doxorubicin—uterine cancer	4.42e-05	0.000709	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	4.4e-05	0.000706	CcSEcCtD
Mefenamic acid—Discomfort—Doxorubicin—uterine cancer	4.38e-05	0.000703	CcSEcCtD
Mefenamic acid—Anorexia—Epirubicin—uterine cancer	4.38e-05	0.000702	CcSEcCtD
Mefenamic acid—Dry mouth—Doxorubicin—uterine cancer	4.34e-05	0.000695	CcSEcCtD
Mefenamic acid—Hypotension—Epirubicin—uterine cancer	4.29e-05	0.000688	CcSEcCtD
Mefenamic acid—Confusional state—Doxorubicin—uterine cancer	4.28e-05	0.000687	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Doxorubicin—uterine cancer	4.25e-05	0.000682	CcSEcCtD
Mefenamic acid—Oedema—Doxorubicin—uterine cancer	4.25e-05	0.000682	CcSEcCtD
Mefenamic acid—Infection—Doxorubicin—uterine cancer	4.22e-05	0.000677	CcSEcCtD
Mefenamic acid—Shock—Doxorubicin—uterine cancer	4.18e-05	0.000671	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Doxorubicin—uterine cancer	4.16e-05	0.000667	CcSEcCtD
Mefenamic acid—Insomnia—Epirubicin—uterine cancer	4.15e-05	0.000666	CcSEcCtD
Mefenamic acid—Tachycardia—Doxorubicin—uterine cancer	4.15e-05	0.000665	CcSEcCtD
Mefenamic acid—Skin disorder—Doxorubicin—uterine cancer	4.13e-05	0.000662	CcSEcCtD
Mefenamic acid—Paraesthesia—Epirubicin—uterine cancer	4.12e-05	0.000662	CcSEcCtD
Mefenamic acid—Dyspnoea—Epirubicin—uterine cancer	4.09e-05	0.000657	CcSEcCtD
Mefenamic acid—Somnolence—Epirubicin—uterine cancer	4.08e-05	0.000655	CcSEcCtD
Mefenamic acid—Anorexia—Doxorubicin—uterine cancer	4.05e-05	0.00065	CcSEcCtD
Mefenamic acid—Dyspepsia—Epirubicin—uterine cancer	4.04e-05	0.000648	CcSEcCtD
Mefenamic acid—Decreased appetite—Epirubicin—uterine cancer	3.99e-05	0.00064	CcSEcCtD
Mefenamic acid—Hypotension—Doxorubicin—uterine cancer	3.97e-05	0.000637	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Epirubicin—uterine cancer	3.96e-05	0.000636	CcSEcCtD
Mefenamic acid—Constipation—Epirubicin—uterine cancer	3.93e-05	0.00063	CcSEcCtD
Mefenamic acid—Insomnia—Doxorubicin—uterine cancer	3.84e-05	0.000617	CcSEcCtD
Mefenamic acid—Paraesthesia—Doxorubicin—uterine cancer	3.82e-05	0.000612	CcSEcCtD
Mefenamic acid—Dyspnoea—Doxorubicin—uterine cancer	3.79e-05	0.000608	CcSEcCtD
Mefenamic acid—Feeling abnormal—Epirubicin—uterine cancer	3.78e-05	0.000607	CcSEcCtD
Mefenamic acid—Somnolence—Doxorubicin—uterine cancer	3.78e-05	0.000606	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Epirubicin—uterine cancer	3.76e-05	0.000602	CcSEcCtD
Mefenamic acid—Dyspepsia—Doxorubicin—uterine cancer	3.74e-05	0.0006	CcSEcCtD
Mefenamic acid—Decreased appetite—Doxorubicin—uterine cancer	3.69e-05	0.000593	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Doxorubicin—uterine cancer	3.67e-05	0.000588	CcSEcCtD
Mefenamic acid—Urticaria—Epirubicin—uterine cancer	3.65e-05	0.000585	CcSEcCtD
Mefenamic acid—Constipation—Doxorubicin—uterine cancer	3.63e-05	0.000583	CcSEcCtD
Mefenamic acid—Abdominal pain—Epirubicin—uterine cancer	3.63e-05	0.000582	CcSEcCtD
Mefenamic acid—Body temperature increased—Epirubicin—uterine cancer	3.63e-05	0.000582	CcSEcCtD
Mefenamic acid—Feeling abnormal—Doxorubicin—uterine cancer	3.5e-05	0.000562	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Doxorubicin—uterine cancer	3.47e-05	0.000557	CcSEcCtD
Mefenamic acid—Urticaria—Doxorubicin—uterine cancer	3.38e-05	0.000542	CcSEcCtD
Mefenamic acid—Body temperature increased—Doxorubicin—uterine cancer	3.36e-05	0.000539	CcSEcCtD
Mefenamic acid—Abdominal pain—Doxorubicin—uterine cancer	3.36e-05	0.000539	CcSEcCtD
Mefenamic acid—Asthenia—Epirubicin—uterine cancer	3.3e-05	0.000529	CcSEcCtD
Mefenamic acid—Pruritus—Epirubicin—uterine cancer	3.25e-05	0.000521	CcSEcCtD
Mefenamic acid—Diarrhoea—Epirubicin—uterine cancer	3.14e-05	0.000504	CcSEcCtD
Mefenamic acid—Asthenia—Doxorubicin—uterine cancer	3.05e-05	0.000489	CcSEcCtD
Mefenamic acid—Dizziness—Epirubicin—uterine cancer	3.04e-05	0.000487	CcSEcCtD
Mefenamic acid—Pruritus—Doxorubicin—uterine cancer	3.01e-05	0.000482	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—CDKN2B—uterine cancer	2.94e-05	0.000466	CbGpPWpGaD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	2.93e-05	0.000464	CbGpPWpGaD
Mefenamic acid—Vomiting—Epirubicin—uterine cancer	2.92e-05	0.000468	CcSEcCtD
Mefenamic acid—Diarrhoea—Doxorubicin—uterine cancer	2.91e-05	0.000466	CcSEcCtD
Mefenamic acid—Rash—Epirubicin—uterine cancer	2.9e-05	0.000465	CcSEcCtD
Mefenamic acid—Dermatitis—Epirubicin—uterine cancer	2.89e-05	0.000464	CcSEcCtD
Mefenamic acid—Headache—Epirubicin—uterine cancer	2.88e-05	0.000462	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—PGR—uterine cancer	2.87e-05	0.000456	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—INHBA—uterine cancer	2.86e-05	0.000454	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—MTHFR—uterine cancer	2.81e-05	0.000446	CbGpPWpGaD
Mefenamic acid—Dizziness—Doxorubicin—uterine cancer	2.81e-05	0.000451	CcSEcCtD
Mefenamic acid—AKR1C3—Disease—HMGA1—uterine cancer	2.76e-05	0.000438	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—CYP19A1—uterine cancer	2.75e-05	0.000436	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—STK11—uterine cancer	2.75e-05	0.000436	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—RRM2—uterine cancer	2.75e-05	0.000436	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—YWHAE—uterine cancer	2.74e-05	0.000435	CbGpPWpGaD
Mefenamic acid—Nausea—Epirubicin—uterine cancer	2.73e-05	0.000438	CcSEcCtD
Mefenamic acid—Vomiting—Doxorubicin—uterine cancer	2.7e-05	0.000433	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—SMAD3—uterine cancer	2.68e-05	0.000426	CbGpPWpGaD
Mefenamic acid—Rash—Doxorubicin—uterine cancer	2.68e-05	0.00043	CcSEcCtD
Mefenamic acid—Dermatitis—Doxorubicin—uterine cancer	2.68e-05	0.000429	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—DCN—uterine cancer	2.67e-05	0.000423	CbGpPWpGaD
Mefenamic acid—Headache—Doxorubicin—uterine cancer	2.66e-05	0.000427	CcSEcCtD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.65e-05	0.00042	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.65e-05	0.00042	CbGpPWpGaD
Mefenamic acid—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	2.64e-05	0.000419	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—FBXW7—uterine cancer	2.63e-05	0.000417	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.58e-05	0.000409	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—AKR1C1—uterine cancer	2.58e-05	0.000409	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—FGFR2—uterine cancer	2.56e-05	0.000406	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NDUFB11—uterine cancer	2.53e-05	0.000401	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—SRD5A2—uterine cancer	2.53e-05	0.000401	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—FBXW7—uterine cancer	2.52e-05	0.0004	CbGpPWpGaD
Mefenamic acid—Nausea—Doxorubicin—uterine cancer	2.52e-05	0.000405	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—CYP11A1—uterine cancer	2.51e-05	0.000398	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.48e-05	0.000393	CbGpPWpGaD
Mefenamic acid—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	2.47e-05	0.000392	CbGpPWpGaD
Mefenamic acid—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	2.47e-05	0.000392	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—MTHFR—uterine cancer	2.46e-05	0.000391	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.46e-05	0.00039	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.46e-05	0.000389	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	2.44e-05	0.000387	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.39e-05	0.000379	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	2.35e-05	0.000372	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.32e-05	0.000368	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—STK11—uterine cancer	2.3e-05	0.000364	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	2.29e-05	0.000364	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	2.29e-05	0.000363	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.16e-05	0.000342	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.16e-05	0.000342	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—SOCS3—uterine cancer	2.15e-05	0.000341	CbGpPWpGaD
Mefenamic acid—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	2.13e-05	0.000337	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—MTHFR—uterine cancer	2.06e-05	0.000327	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CDKN2B—uterine cancer	2.06e-05	0.000327	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NDUFB11—uterine cancer	2.01e-05	0.000318	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—SRD5A2—uterine cancer	2.01e-05	0.000318	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IGF1R—uterine cancer	2e-05	0.000317	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CDKN2B—uterine cancer	1.98e-05	0.000314	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.95e-05	0.000309	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.95e-05	0.000309	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PGR—uterine cancer	1.93e-05	0.000307	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—SMAD3—uterine cancer	1.88e-05	0.000298	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—AKR1B10—uterine cancer	1.86e-05	0.000296	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—STK11—uterine cancer	1.85e-05	0.000293	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—CYP19A1—uterine cancer	1.85e-05	0.000293	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—YWHAE—uterine cancer	1.84e-05	0.000292	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.84e-05	0.000292	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—AKR1B1—uterine cancer	1.83e-05	0.00029	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—STAR—uterine cancer	1.83e-05	0.00029	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.82e-05	0.000288	CbGpPWpGaD
Mefenamic acid—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	1.81e-05	0.000287	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.81e-05	0.000286	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—SMAD3—uterine cancer	1.81e-05	0.000286	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—FGFR2—uterine cancer	1.79e-05	0.000284	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—FBXW7—uterine cancer	1.77e-05	0.00028	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.73e-05	0.000275	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—FGFR2—uterine cancer	1.72e-05	0.000273	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.68e-05	0.000267	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MTHFR—uterine cancer	1.66e-05	0.000263	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.65e-05	0.000262	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—SRD5A2—uterine cancer	1.63e-05	0.000259	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NDUFB11—uterine cancer	1.63e-05	0.000259	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—ERBB2—uterine cancer	1.61e-05	0.000255	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.59e-05	0.000252	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.58e-05	0.000251	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PTEN—uterine cancer	1.56e-05	0.000248	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.56e-05	0.000247	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—STK11—uterine cancer	1.55e-05	0.000245	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—RNF43—uterine cancer	1.54e-05	0.000245	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—ESR1—uterine cancer	1.53e-05	0.000243	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.5e-05	0.000238	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—EP300—uterine cancer	1.49e-05	0.000237	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—CDKN1B—uterine cancer	1.49e-05	0.000236	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.47e-05	0.000234	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—AKR1B1—uterine cancer	1.45e-05	0.00023	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—STAR—uterine cancer	1.45e-05	0.00023	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SOCS3—uterine cancer	1.45e-05	0.00023	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—TP53—uterine cancer	1.44e-05	0.000228	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.44e-05	0.000228	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—POLD1—uterine cancer	1.43e-05	0.000227	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.43e-05	0.000227	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—CTNNB1—uterine cancer	1.41e-05	0.000223	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—MTHFR—uterine cancer	1.39e-05	0.00022	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN2B—uterine cancer	1.39e-05	0.00022	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—PTEN—uterine cancer	1.37e-05	0.000217	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.37e-05	0.000217	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CCL2—uterine cancer	1.35e-05	0.000214	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IGF1R—uterine cancer	1.35e-05	0.000213	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—AKR1C1—uterine cancer	1.34e-05	0.000213	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SRD5A2—uterine cancer	1.33e-05	0.000211	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NDUFB11—uterine cancer	1.33e-05	0.000211	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—EP300—uterine cancer	1.31e-05	0.000207	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.3e-05	0.000206	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.29e-05	0.000205	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—AKR1C1—uterine cancer	1.27e-05	0.000202	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SMAD3—uterine cancer	1.26e-05	0.000201	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.22e-05	0.000194	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—NRAS—uterine cancer	1.22e-05	0.000194	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.22e-05	0.000193	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—FGFR2—uterine cancer	1.21e-05	0.000191	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—RRM2—uterine cancer	1.2e-05	0.00019	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—STAR—uterine cancer	1.18e-05	0.000187	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKR1B1—uterine cancer	1.18e-05	0.000187	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.17e-05	0.000185	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—DCN—uterine cancer	1.16e-05	0.000184	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PTEN—uterine cancer	1.15e-05	0.000182	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—POLD1—uterine cancer	1.14e-05	0.000181	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—ERBB2—uterine cancer	1.13e-05	0.000179	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PIK3CA—uterine cancer	1.1e-05	0.000175	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.1e-05	0.000175	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—DCN—uterine cancer	1.1e-05	0.000174	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—EP300—uterine cancer	1.1e-05	0.000174	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CYP11A1—uterine cancer	1.09e-05	0.000173	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—ERBB2—uterine cancer	1.08e-05	0.000172	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CXCL8—uterine cancer	1.07e-05	0.000169	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—AKR1C1—uterine cancer	1.06e-05	0.000169	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—KRAS—uterine cancer	1.05e-05	0.000167	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CDKN1B—uterine cancer	1.04e-05	0.000165	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—AKR1C3—uterine cancer	1.03e-05	0.000164	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—ESR1—uterine cancer	1.03e-05	0.000164	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.01e-05	0.000161	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CDKN1B—uterine cancer	1e-05	0.000159	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CTNNB1—uterine cancer	9.85e-06	0.000156	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	9.8e-06	0.000155	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—AKR1C3—uterine cancer	9.79e-06	0.000155	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—PIK3CA—uterine cancer	9.67e-06	0.000153	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKR1B1—uterine cancer	9.61e-06	0.000152	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—STAR—uterine cancer	9.61e-06	0.000152	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—PTEN—uterine cancer	9.6e-06	0.000152	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HMGA1—uterine cancer	9.54e-06	0.000151	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	9.5e-06	0.000151	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—RRM2—uterine cancer	9.49e-06	0.000151	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CTNNB1—uterine cancer	9.47e-06	0.00015	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—POLD1—uterine cancer	9.26e-06	0.000147	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PTEN—uterine cancer	9.23e-06	0.000146	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—DCN—uterine cancer	9.21e-06	0.000146	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—EP300—uterine cancer	9.16e-06	0.000145	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CCL2—uterine cancer	9.09e-06	0.000144	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—AKT1—uterine cancer	9.02e-06	0.000143	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—HRAS—uterine cancer	8.95e-06	0.000142	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—EP300—uterine cancer	8.8e-06	0.00014	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FBXW7—uterine cancer	8.72e-06	0.000138	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP11A1—uterine cancer	8.68e-06	0.000138	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—VEGFA—uterine cancer	8.67e-06	0.000138	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKR1C1—uterine cancer	8.66e-06	0.000137	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—NRAS—uterine cancer	8.57e-06	0.000136	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	8.27e-06	0.000131	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—NRAS—uterine cancer	8.23e-06	0.000131	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—AKR1C3—uterine cancer	8.2e-06	0.00013	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PIK3CA—uterine cancer	8.1e-06	0.000128	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—STK11—uterine cancer	8.04e-06	0.000128	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CYP19A1—uterine cancer	8.04e-06	0.000128	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—AKT1—uterine cancer	7.9e-06	0.000125	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PTEN—uterine cancer	7.73e-06	0.000123	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—RRM2—uterine cancer	7.72e-06	0.000122	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—ERBB2—uterine cancer	7.58e-06	0.00012	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.55e-06	0.00012	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—POLD1—uterine cancer	7.54e-06	0.00012	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—DCN—uterine cancer	7.5e-06	0.000119	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—KRAS—uterine cancer	7.37e-06	0.000117	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—EP300—uterine cancer	7.37e-06	0.000117	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.2e-06	0.000114	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CXCL8—uterine cancer	7.18e-06	0.000114	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—KRAS—uterine cancer	7.08e-06	0.000112	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP11A1—uterine cancer	7.06e-06	0.000112	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKR1C1—uterine cancer	7.05e-06	0.000112	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN1B—uterine cancer	7.02e-06	0.000111	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN2B—uterine cancer	6.84e-06	0.000108	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—PIK3CA—uterine cancer	6.77e-06	0.000107	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKR1C3—uterine cancer	6.67e-06	0.000106	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CTNNB1—uterine cancer	6.63e-06	0.000105	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—AKT1—uterine cancer	6.62e-06	0.000105	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TP53—uterine cancer	6.55e-06	0.000104	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PIK3CA—uterine cancer	6.51e-06	0.000103	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PTEN—uterine cancer	6.46e-06	0.000102	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP19A1—uterine cancer	6.39e-06	0.000101	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—STK11—uterine cancer	6.39e-06	0.000101	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—RRM2—uterine cancer	6.29e-06	9.97e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—HRAS—uterine cancer	6.27e-06	9.94e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—SMAD3—uterine cancer	6.24e-06	9.9e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—EP300—uterine cancer	6.16e-06	9.77e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—DCN—uterine cancer	6.1e-06	9.68e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—MTHFR—uterine cancer	6.05e-06	9.59e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—HRAS—uterine cancer	6.02e-06	9.55e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.99e-06	9.51e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FGFR2—uterine cancer	5.95e-06	9.44e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—VEGFA—uterine cancer	5.84e-06	9.25e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—NRAS—uterine cancer	5.76e-06	9.14e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP11A1—uterine cancer	5.75e-06	9.12e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MTHFR—uterine cancer	5.73e-06	9.09e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.72e-06	9.07e-05	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—AKT1—uterine cancer	5.53e-06	8.78e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PIK3CA—uterine cancer	5.45e-06	8.64e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKR1C3—uterine cancer	5.43e-06	8.61e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.33e-06	8.45e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—AKT1—uterine cancer	5.32e-06	8.43e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—STK11—uterine cancer	5.2e-06	8.24e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP19A1—uterine cancer	5.2e-06	8.24e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—KRAS—uterine cancer	4.96e-06	7.87e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.88e-06	7.74e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—MTHFR—uterine cancer	4.8e-06	7.61e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.65e-06	7.38e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PIK3CA—uterine cancer	4.56e-06	7.23e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—AKT1—uterine cancer	4.45e-06	7.06e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TP53—uterine cancer	4.41e-06	6.99e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—STK11—uterine cancer	4.23e-06	6.71e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP19A1—uterine cancer	4.23e-06	6.71e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.23e-06	6.71e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—HRAS—uterine cancer	4.22e-06	6.69e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.97e-06	6.3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—MTHFR—uterine cancer	3.9e-06	6.19e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.79e-06	6e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ERBB2—uterine cancer	3.74e-06	5.93e-05	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—AKT1—uterine cancer	3.72e-06	5.9e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN1B—uterine cancer	3.46e-06	5.49e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.44e-06	5.46e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTEN—uterine cancer	3.36e-06	5.33e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CTNNB1—uterine cancer	3.27e-06	5.19e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—EP300—uterine cancer	3.21e-06	5.09e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PTEN—uterine cancer	3.19e-06	5.06e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—MTHFR—uterine cancer	3.18e-06	5.04e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—EP300—uterine cancer	3.04e-06	4.82e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NRAS—uterine cancer	2.84e-06	4.51e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.8e-06	4.44e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PTEN—uterine cancer	2.67e-06	4.23e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—EP300—uterine cancer	2.55e-06	4.04e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KRAS—uterine cancer	2.45e-06	3.88e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PIK3CA—uterine cancer	2.37e-06	3.76e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PIK3CA—uterine cancer	2.25e-06	3.57e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTEN—uterine cancer	2.17e-06	3.45e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HRAS—uterine cancer	2.08e-06	3.3e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—EP300—uterine cancer	2.07e-06	3.29e-05	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—AKT1—uterine cancer	1.94e-06	3.07e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PIK3CA—uterine cancer	1.88e-06	2.99e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—AKT1—uterine cancer	1.84e-06	2.91e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTEN—uterine cancer	1.77e-06	2.8e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—EP300—uterine cancer	1.69e-06	2.67e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—AKT1—uterine cancer	1.54e-06	2.44e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PIK3CA—uterine cancer	1.53e-06	2.43e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—AKT1—uterine cancer	1.25e-06	1.99e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.25e-06	1.98e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—AKT1—uterine cancer	1.02e-06	1.62e-05	CbGpPWpGaD
